| Patient | Helen Keller |
|---|---|
| Date of birth | 1947-06-27 |
| Identifiers | MRN HR-ET006-SYN; SSN (made up) 000-06-2195 |
| Document date | 2026-11-01 |
| Author | Philippa Strand, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit to establish care after a fall at home. Concerns: Fell on her back steps three weeks ago where the handrail stops one step short; no injury, but she wants to keep walking outdoors and traveling for her work; Wants her visits conducted directly with her through a qualified tactile interpreter, with enough time and with written materials in braille; Wants a plan so that her way of communicating is respected if she is ever in hospital. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Nitrofurantoin monohydrate/macrocrystals 100 mg oral capsule, one capsule by mouth twice a day for 5 days | One capsule by mouth twice a day with food for 5 days | Oral route | 2026-08-03 to 2026-08-07 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Orthostatic vital signs: lying 132/76 mmHg, pulse 70; standing at 1 minute 128/74 mmHg, pulse 76; at 3 minutes 130/76 mmHg, pulse 74; no orthostatic hypotension and no dizziness | 2026-03-09 to 2026-03-09 | completed | S |
| Dual-energy X-ray absorptiometry of the hip and lumbar spine: femoral neck T-score -1.9 and lumbar spine T-score -1.4 (low bone mass); 10-year FRAX risk 15 percent for a major osteoporotic fracture and 2.4 percent for hip fracture | 2026-03-23 to 2026-03-23 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2019-05-06 | Tdap vaccine | completed | S |
| 2023-04-17 | Recombinant zoster vaccine, two-dose series completed | completed | S |
| 2024-03-11 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2024-10-07 | Respiratory syncytial virus vaccine, single dose | completed | S |
| 2025-10-13 | High-dose influenza vaccine, 2025-2026 season | completed | S |
| 2026-10-19 | High-dose influenza vaccine, 2026-2027 season | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| February 1882 | Febrile illness at 19 months, called acute congestion of the stomach and brain at the time, after which she was deaf and blind | D (CLM-0002) |
| February 1882 | Cause of the 1882 illness unknown; scarlet fever, meningitis, and rubella have been proposed retrospectively (not established) | R (CLM-0003) |
| September 1911 | Receipt for an artificial eye; which eye and the reason are not recorded | D (CLM-0008) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| father | Died in 1896; cause not recorded in the cited source | D (CLM-0010) | |
| mother | Died in 1921; cause not recorded in the cited source | D (CLM-0010) |
| Concern | Status | Evidence |
|---|---|---|
| Fell on her back steps three weeks ago where the handrail stops one step short; no injury, but she wants to keep walking outdoors and traveling for her work | active | S |
| Wants her visits conducted directly with her through a qualified tactile interpreter, with enough time and with written materials in braille | active | S |
| Wants a plan so that her way of communicating is respected if she is ever in hospital | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 13 on 2026-03-09; Sodium [Moles/volume] in Serum or Plasma 139 on 2026-03-09; Potassium [Moles/volume] in Serum or Plasma 4.4 on 2026-03-09; Creatinine [Mass/volume] in Serum or Plasma 0.82 on 2026-03-09; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 73 on 2026-03-09; Glucose [Mass/volume] in Serum or Plasma 94 on 2026-03-09; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 31 on 2026-03-09; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 520 on 2026-03-09; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 1 on 2026-10-19; PROMIS physical function - version 1.0 Tscore 46 on 2026-09-14; DXA Femur [T-score] Bone density -1.9 on 2026-03-23; DXA Lumbar spine [T-score] Bone density -1.4 on 2026-03-23; Total score [AUDIT-C] 2 on 2026-10-19 [S]
Strengths and supports: Supports: her assistant, a wide circle of friends and colleagues, and the deafblind community [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Blindness of both eyes with no light perception since an illness at 19 months; part of lifelong deafblindness, linked to the documented 1882 illness | active | confirmed | H54.0X55 | S — Documented lifelong blindness carried into the synthetic modern record; the cause of the illness is not established. |
| Profound bilateral deafness since the same illness; part of lifelong deafblindness, linked to the documented 1882 illness | active | confirmed | H91.93 | S — Documented lifelong deafness carried into the synthetic modern record; the type of hearing loss was never established, so the unspecified code is used. |
| Wears an artificial eye | active | confirmed | Z97.0 | S — Synthetic modern entry echoing the documented 1911 receipt for an artificial eye; which eye is not recorded. |
| Fall at home without injury, with reduced leg strength and balance on testing; increased fall risk | active | confirmed | Z91.81 | S — Synthetic presenting problem; no fall is documented in the cited sources. |
| Acute uncomplicated cystitis, treated with nitrofurantoin, resolved | resolved | confirmed | N30.00 | S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-09 | Hemoglobin [Mass/volume] in Blood | 13 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-03-09 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-09 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-09 | Creatinine [Mass/volume] in Serum or Plasma | 0.82 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-03-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 73 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-09 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-09 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 31 | ng/mL | 30-100 ng/mL | Normal | S |
| 2026-03-09 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 520 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-03-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 2026-03-09 | PROMIS physical function - version 1.0 Tscore | 41 | {score} | S | ||
| 2026-03-23 | DXA Femur [T-score] Bone density | -1.9 | {T-score} | >=-1 | Low | S |
| 2026-03-23 | DXA Lumbar spine [T-score] Bone density | -1.4 | {T-score} | >=-1 | Low | S |
| 2026-06-15 | PROMIS physical function - version 1.0 Tscore | 44 | {score} | S | ||
| 2026-09-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 2026-09-14 | PROMIS physical function - version 1.0 Tscore | 46 | {score} | S | ||
| 2026-10-19 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 1 | {score} | S | ||
| 2026-10-19 | Total score [AUDIT-C] | 2 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-09 | Body height | 165 | cm | S |
| 2026-03-09 | Body weight | 61 | kg | S |
| 2026-03-09 | Body mass index (BMI) [Ratio] | 22.4 | kg/m2 | S |
| 2026-03-09 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-03-09 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-03-09 | Heart rate | 72 | /min | S |
| 2026-03-09 | Respiratory rate | 14 | /min | S |
| 2026-03-09 | Body temperature | 36.6 | Cel | S |
| 2026-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-03-23 | Body height | 165 | cm | S |
| 2026-03-23 | Body weight | 61.2 | kg | S |
| 2026-03-23 | Body mass index (BMI) [Ratio] | 22.5 | kg/m2 | S |
| 2026-03-23 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-03-23 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-03-23 | Heart rate | 70 | /min | S |
| 2026-03-23 | Respiratory rate | 14 | /min | S |
| 2026-03-23 | Body temperature | 36.5 | Cel | S |
| 2026-03-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-06-15 | Body height | 165 | cm | S |
| 2026-06-15 | Body weight | 61.4 | kg | S |
| 2026-06-15 | Body mass index (BMI) [Ratio] | 22.6 | kg/m2 | S |
| 2026-06-15 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-06-15 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-06-15 | Heart rate | 68 | /min | S |
| 2026-06-15 | Respiratory rate | 14 | /min | S |
| 2026-06-15 | Body temperature | 36.6 | Cel | S |
| 2026-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-14 | Body height | 165 | cm | S |
| 2026-09-14 | Body weight | 61 | kg | S |
| 2026-09-14 | Body mass index (BMI) [Ratio] | 22.4 | kg/m2 | S |
| 2026-09-14 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-09-14 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-09-14 | Heart rate | 70 | /min | S |
| 2026-09-14 | Respiratory rate | 14 | /min | S |
| 2026-09-14 | Body temperature | 36.6 | Cel | S |
| 2026-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-08-03 | Body height | 165 | cm | S |
| 2026-08-03 | Body weight | 60.8 | kg | S |
| 2026-08-03 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 2026-08-03 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-08-03 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-08-03 | Heart rate | 84 | /min | S |
| 2026-08-03 | Respiratory rate | 16 | /min | S |
| 2026-08-03 | Body temperature | 37.2 | Cel | S |
| 2026-08-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-19 | Body height | 165 | cm | S |
| 2026-10-19 | Body weight | 61.1 | kg | S |
| 2026-10-19 | Body mass index (BMI) [Ratio] | 22.4 | kg/m2 | S |
| 2026-10-19 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-10-19 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-10-19 | Heart rate | 68 | /min | S |
| 2026-10-19 | Respiratory rate | 14 | /min | S |
| 2026-10-19 | Body temperature | 36.6 | Cel | S |
| 2026-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-03-09 | New patient visit to establish care after a fall at home | finished | S |
| 2026-03-23 | Two-week fall-risk and bone density review, and geriatric medicine consultation | finished | S |
| 2026-06-15 | Three-month falls prevention and function review | finished | S |
| 2026-09-14 | Six-month falls prevention and function review | finished | S |
| 2026-08-03 | Same-day sick visit for urinary symptoms | finished | S |
| 2026-10-19 | Subsequent annual wellness visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Fall evaluation by CDC STEADI: fall history, Timed Up and Go, 30-second chair stand, four-stage balance test, orthostatic blood pressure, medication review, feet and footwear, and vitamin D | completed | GL-STEADI, GL-USPSTF-FALLS-2024 | S |
| Home strength and balance exercise with a physical therapist twice a week for 12 weeks, then daily on her own, with a qualified tactile interpreter at the therapy sessions | completed | GL-USPSTF-FALLS-2024, GL-STEADI | S |
| Geriatric medicine consultation for a comprehensive geriatric assessment adapted for deafblindness, including fall risk, cognition, and future care planning | completed | GL-STEADI, GL-DDBHH-2025 | S |
| Communication access: the clinic books and pays for a qualified tactile interpreter for every visit, she chooses the method, staff do not rely on her assistant to interpret, appointments are double length, and all documents are given in braille and accessible electronic text | completed | GL-DDBHH-2025 | S |
| Occupational therapy home safety visit: handrails on both sides, tactile edge strips on steps, clear routes, vibrating smoke and carbon monoxide alarms with a bed shaker, and a wearable alert button | completed | GL-STEADI | S |
| Bone density screening by DXA, with FRAX risk, dietary calcium and vitamin D advice, and treatment only if risk reaches the treatment threshold | completed | GL-USPSTF-OSTEO-2025 | S |
| Protect touch and skin: check hand and foot sensation, skin, and the artificial eye socket at each preventive visit, and see the ocularist yearly to polish the prosthesis | completed | GL-STEADI, GL-AWV-CMS | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| No further falls, and a 30-second chair stand of 12 or more by the six-month review | 2026-09-14 | completed | No falls in six months; chair stand 12 | S |
| Home changes complete: handrails on both sides of every step, tactile edge strips, and vibrating smoke and carbon monoxide alarms with a bed shaker | 2026-09-14 | completed | All installed after the occupational therapy home visit | S |
| A communication access plan in her chart: a qualified tactile interpreter booked by the clinic for every visit, double-length appointments, braille after-visit summaries, and a hospital communication passport | 2026-03-23 | completed | Plan recorded and passport written in braille and print | S |
| Keep traveling to speak, with a travel plan for falls and illness | 2026-09-14 | completed | Two speaking trips completed with a sighted guide | S |